280
Participants
Start Date
December 17, 2024
Primary Completion Date
January 31, 2030
Study Completion Date
October 31, 2031
RP2
Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
Ipilimumab
Ipilimumab: human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
Nivolumab
Nivolumab: Anti-PD-1 Monoclonal antibody
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
Thomas Jefferson University, Philadelphia
RECRUITING
Georgetown University Medical Center, Washington D.C.
RECRUITING
Duke University Medical Center, Durham
RECRUITING
Emory Winship Cancer Institute, Atlanta
RECRUITING
Sylvester Comprehensive Cancer Center, Miami
RECRUITING
Sarah Cannon Research Institute, Nashville
RECRUITING
Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic), Nashville
RECRUITING
The West Clinic, PLLC dba West Cancer Center, Germantown
RECRUITING
The Ohio State University, Columbus
RECRUITING
University of Iowa, Iowa City
RECRUITING
University Of Wisconsin Carbone Cancer Center - University Hospital, Madison
RECRUITING
Northwestern Memorial Hospital, Chicago
RECRUITING
University of Chicago Medical Center, Chicago
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
The University Of Texas Md Anderson Cancer Center, Houston
RECRUITING
The Melanoma & Skin Cancer Institute, Englewood
RECRUITING
HonorHealth Research Insisute, Scottsdale
RECRUITING
The Angeles Clinic and Research Institute, Los Angeles
RECRUITING
University of California Los Angeles, Los Angeles
RECRUITING
UC San Diego Moores Cancer Center, La Jolla
RECRUITING
Stanford Cancer Institute, Palo Alto
RECRUITING
Massachusetts General Hospital, Boston
Replimune Inc.
INDUSTRY